Is glyceryl trinitrate (nitroglycerin) contraindicated for chest pain in a patient with severe aortic stenosis?

GTN is NOT Absolutely Contraindicated in Severe Aortic Stenosis for Chest Pain

While traditional teaching has considered nitrates contraindicated in severe aortic stenosis, current evidence and guidelines do not list aortic stenosis as an absolute contraindication—rather, nitrates should be used with extreme caution, careful hemodynamic monitoring, and only when the patient is hemodynamically stable.

Guideline-Based Contraindications to Nitrates

The most recent ACC/AHA guidelines 1 and prior iterations 2, 3, 2, 4, 5, 6 consistently list the following as Class III (Harm) contraindications for nitroglycerin:

• Systolic blood pressure <90 mm Hg or ≥30 mm Hg below baseline
• Severe bradycardia (<50 bpm)
• Tachycardia (>100 bpm) in the absence of heart failure
• Suspected right ventricular infarction
• Recent phosphodiesterase-5 inhibitor use (within 24h for sildenafil/vardenafil, 48h for tadalafil)

Notably absent from this list: aortic stenosis 1, 2, 3, 2, 4, 5, 6.

The FDA drug label 7 lists contraindications as: early MI, severe anemia, increased intracranial pressure, hypersensitivity, PDE-5 inhibitor use, and guanylate cyclase stimulator use—but not aortic stenosis.

The Theoretical Concern vs. Clinical Reality

The traditional concern stems from the pathophysiology: severe aortic stenosis creates fixed cardiac output, and nitrate-induced vasodilation could theoretically precipitate profound hypotension by reducing preload in a system that cannot compensate by increasing stroke volume.

However, recent clinical evidence challenges this dogma:

• A retrospective cohort study 8 of 195 episodes of acute pulmonary edema (65 with severe AS, 65 with moderate AS, 65 without AS) found that severe aortic stenosis was NOT associated with increased risk of clinically relevant hypotension requiring intervention after nitroglycerin administration (adjusted OR 0.99,95% CI 0.41-2.41)
• The incidence of clinically relevant hypotension was similar: 26.2% in moderate/severe AS vs. 23.1% in no AS
• Sustained hypotension occurred more frequently in severe AS (29.2% vs. 13.8%), but this did not reach statistical significance after adjustment (adjusted OR 2.34,95% CI 0.91-6.01)

Clinical Approach: When and How to Use Nitrates in Severe AS

Use nitrates in severe AS patients with chest pain ONLY when:

1. Hemodynamically stable (SBP ≥90-100 mm Hg, ideally >110 mm Hg)
2. No other absolute contraindications exist (bradycardia, tachycardia without HF, RV infarction, recent PDE-5 inhibitor)
3. Continuous monitoring is available
4. Start with lower doses: sublingual 0.3-0.4 mg, reassess after each dose 1, 2
5. Have IV access and be prepared to treat hypotension with fluids/vasopressors

Avoid or use extreme caution when:

• Patient has symptoms of low cardiac output (syncope, presyncope, severe dyspnea at rest)
• Baseline SBP <110 mm Hg
• Concomitant pulmonary edema with severe AS (higher risk scenario per 8)

Key Clinical Pitfalls

1. Don't withhold nitrates reflexively in stable severe AS patients with ACS—the risk of ongoing ischemia may outweigh hypotension risk
2. Monitor blood pressure closely after each sublingual dose (every 5 minutes)
3. Consider the clinical context: Nitrates for ACS with severe AS is different from nitrates for acute pulmonary edema with severe AS (latter has higher risk 8)
4. Pre-NTG blood pressure is the strongest predictor of post-NTG hypotension 9—use this to guide decision-making more than the presence of AS alone

Bottom Line Algorithm

For chest pain in severe AS:

• SBP ≥110 mm Hg + no other contraindications → Cautious trial of sublingual NTG 0.3-0.4 mg with close monitoring
• SBP 90-110 mm Hg → Consider alternative anti-ischemic therapy first (morphine, beta-blockers if appropriate); NTG only if benefits clearly outweigh risks
• SBP <90 mm Hg → Absolute contraindication, do not give nitrates 1, 2, 3

The 2025 ACC/AHA guidelines 1 emphasize using nitrates for hemodynamically stable patients (SBP ≥90 mm Hg), and this threshold should be respected even more stringently in severe AS patients, with consideration for a higher threshold (≥110 mm Hg) given the fixed cardiac output physiology.